Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of nemolizumab in Japanese patients with atopic dermatitis and moderate to severe pruritus
jRCT2080223838Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nemolizumab in atopic dermatitis (AD), sponsored by Maruho Co., Ltd. Primary endpoint: Long-term safety of nemolizumab. Started Mar 2018; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080223838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223838.